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2407OBJECTIVE To review the literature systematically to determine whether initiation of beta blockade within 45 days prior
to noncardiac surgery reduces 30-day cardiovascular morbidity and mortality rates.
METHODS PubMed (up to April 2013), Embase (up to April 2013), Cochrane Central Register of Controlled Trials (up to
March 2013), and conference abstracts (January 2011 to April 2013) were searched for randomized controlled trials (RCTs)
and cohort studies comparing perioperative beta blockade with inactive control during noncardiac surgery. Pooled relative
risks (RRs) were calculated under the random-effects model. We conducted subgroup analyses to assess how the
DECREASE-I (Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography), DECREASE-IV, and
POISE-1 (Perioperative Ischemic Evaluation) trials inﬂuenced our conclusions.
RESULTS We identiﬁed 17 studies, of which 16 were RCTs (12,043 participants) and 1 was a cohort study (348
participants). Aside from the DECREASE trials, all other RCTs initiated beta blockade within 1 day or less prior to
surgery. Among RCTs, beta blockade decreased nonfatal myocardial infarction (MI) (RR: 0.69; 95% conﬁdence interval
[CI]: 0.58 to 0.82) but increased nonfatal stroke (RR: 1.76; 95% CI:1.07 to 2.91), hypotension (RR: 1.47; 95% CI: 1.34
to 1.60), and bradycardia (RR: 2.61; 95% CI: 2.18 to 3.12). These ﬁndings were qualitatively unchanged after the
DECREASE and POISE-1 trials were excluded. Effects on mortality rate differed signiﬁcantly between the DECREASE
trials and other trials. Beta blockers were associated with a trend toward reduced all-cause mortality rate in the
DECREASE trials (RR: 0.42; 95% CI: 0.15 to 1.22) but with increased all-cause mortality rate in other trials (RR: 1.30;
95% CI: 1.03 to 1.64). Beta blockers reduced cardiovascular mortality rate in the DECREASE trials (RR:0.17; 95% CI:
0.05 to 0.64) but were associated with trends toward increased cardiovascular mortality rate in other trials (RR: 1.25;
95% CI: 0.92 to 1.71). These differences were qualitatively unchanged after the POISE-1 trial was excluded.
CONCLUSIONS Perioperative beta blockade started within 1 day or less before noncardiac surgery prevents
nonfatal MI but increases risks of stroke, death, hypotension, and bradycardia. Without the controversial DECREASE
studies, there are insufﬁcient data on beta blockade started 2 or more days prior to surgery. Multicenter RCTs are
needed to address this knowledge gap.TABLE OF CONTENTSINTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2408
METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2408
Eligibility Criteria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2408
Search Strategy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2408
Methods of Review . . . . . . . . . . . . . . . . . . . . . . . . . . . 2409
Statistical Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2409
RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2409
Nonfatal MI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2410
Nonfatal Stroke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2410
All-Cause Death . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2410
Cardiovascular Death . . . . . . . . . . . . . . . . . . . . . . . . . . 2410
Perioperative Adverse Effects . . . . . . . . . . . . . . . . . . . 2410
Post Hoc Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2410
Publication Bias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2410DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2410
Inﬂuence of the DECREASE Trials . . . . . . . . . . . . . . . 2411
Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2411
Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2412
TABLES AND FIGURES
Table 1. Summary of Included Studies . . . . . . . . . . . . 2413
Table 2. Perioperative Beta-Blocker Regimens,
Duration of Follow-Up, and Comparison Arms
in Included Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . 2415
Figure 1. Effect of Perioperative Beta Blockade on
In-Hospital or 30-Day Nonfatal MI in RCTs Within
Subgroups Deﬁned by DECREASE Trials Versus
Other Trials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2417
Figure 2. Effect of Perioperative Beta Blockade on
In-Hospital or 30-Day Nonfatal MI in RCTs After
Exclusion of the DECREASE Family of Trials,
Within Subgroups Deﬁned by the POISE-1 Trial
Versus Other Trials . . . . . . . . . . . . . . . . . . . . . . . . . . . 2418
Wijeysundera et al. J A C C V O L . 6 4 , N O . 2 2 , 2 0 1 4
ACC/AHA Perioperative Guideline Systematic Review D E C E M B E R 9 , 2 0 1 4 : 2 4 0 6 – 2 5
2408Figure 3. Effect of Perioperative Beta Blockade on
In-Hospital or 30-Day Nonfatal Stroke in RCTs
Within Subgroups Deﬁned by DECREASE Trials
Versus Other Trials . . . . . . . . . . . . . . . . . . . . . . . . . . . 2419
Figure 4. Effect of Perioperative Beta Blockade on
In-Hospital or 30-Day Nonfatal Stroke in RCTs
After Exclusion of the DECREASE Family of Trials,
Within Subgroups Deﬁned by the POISE-1 Trial
Versus Other Trials . . . . . . . . . . . . . . . . . . . . . . . . . . . 2420
Figure 5. Effect of Perioperative Beta Blockade on
In-Hospital or 30-Day Mortality Rate in RCTs
Within Subgroups Deﬁned by DECREASE Trials
Versus Other Trials . . . . . . . . . . . . . . . . . . . . . . . . . . . 2421
Figure 6. Effect of Perioperative Beta Blockade on
In-Hospital or 30-Day Mortality Rate in RCTs
After Exclusion of the DECREASE Family of Trials,
Within Subgroups Deﬁned by POISE-1 Trial Versus
Other Trials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2422
REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2423
APPENDIX 1
Author Relationships With Industry and
Other Entities (Relevant) . . . . . . . . . . . . . . . . . . . . . . . 2425INTRODUCTION
Perioperative cardiac complications are an important
concern for the 230 million individuals who undergo
surgery worldwide every year (1). After surgery, 2% of
these patients suffer major cardiac complications (2), and
8% show evidence of signiﬁcant myocardial injury (3).
Perioperative beta blockade showed early promise as a
means of preventing these complications, with enthu-
siasm driven by promising results in 2 RCTs (4,5).
Consequently, perioperative beta blockade was recom-
mended for a fairly broad spectrum of surgical patients in
initial versions of the American College of Cardiology
(ACC)/American Heart Association (AHA) clinical practice
guidelines (CPGs). For example, among patients with un-
treated hypertension, known coronary artery disease, or
cardiac risk factors, perioperative beta blockade received a
Class II recommendation in 1996 (6) and a Class IIa recom-
mendation in 2002 (7). Nonetheless, for several reasons, the
strength and scope of these recommendations diminished
over successive iterations of these CPGs (8–10). First, subse-
quent moderate-sized RCTs failed to demonstrate signiﬁcant
beneﬁts from beta blockade (11,12). Second, in the POISE-1
trial of almost 9000 participants, it was found that although
perioperative beta blockade prevented perioperative MI, this
beneﬁt was accompanied by increased rates of death, stroke,
hypotension, and bradycardia (13). Although the POISE-1 trial
has been criticized for starting long-acting beta blockers at
high doses shortly prior to surgery (14), its results highlightedthe potential for important risks from perioperative beta
blockade. Third, the validity of work led by Poldermans,
including 2 inﬂuential perioperative beta-blockade RCTs
(5,15), has been scrutinized because of concerns about scien-
tiﬁc misconduct (16,17). Consequently, it has been suggested
that CPGs re-evaluate and potentially exclude these data from
the evidence base used to inform recommendations about
perioperative beta blockade (18).
On the basis of the “American College of Cardiology
Foundation/AHA clinical practice guideline methodology
summit report” (19), the ACC/AHA Task Force on
Practice Guidelines (Task Force) recognized the need for
an objective review of available RCTs and observational
studies by an independent Evidence Review Committee
(ERC) to inform any recommendations about periopera-
tive beta blockade in the 2014 ACC/AHA perioperative
CPG (20). The ERC undertook this review to address a
speciﬁc clinical question framed by the writing committee
for this CPG (with input from the ERC): What is the evi-
dence that initiating beta blockade within 45 days prior to
noncardiac surgery reduces perioperative cardiovascular
morbidity and mortality within 30 days after surgery?
Our objectives were to summarize evidence relevant to
this question and assess the degree to which studies
led by Poldermans inﬂuenced our overall conclusions.
METHODS
This systematic review adhered to the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses
statement (21) and to recommendations of the “Amer-
ican College of Cardiology Foundation/AHA clinical
practice guideline methodology summit report” (19).
Eligibility Criteria
We included RCTs or cohort studies comparing perioper-
ative beta blockade against inactive control, including
placebo, in adults ($18 years of age) undergoing noncar-
diac surgery. Otherwise eligible cohort studies were
included only if the sample size exceeded 100 participants.
Perioperative beta blockade was deﬁned as beta-blocker
therapy (except sotalol) started at any point between 45
days prior to surgery and 24 hours after surgery. Treatment
also had to be continued until at least hospital discharge or
the second day after surgery (whichever occurred ﬁrst).
This minimum duration of postoperative therapy was
speciﬁed because perioperative MI generally occurs
during the ﬁrst 3 days after surgery (22). Otherwise eligible
studies also had to report any of 4 prespeciﬁed outcomes:
MI, all-cause death, cardiovascular death, or stroke.
Search Strategy
Eligible studies were identiﬁed using PubMed (up to April
2013), Embase (up to April 2013), and the Cochrane
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The search strategies used within these databases are
presented in the Online Data Supplement 1 to 3. The ERC
also hand-searched abstracts from conferences of speciﬁc
scientiﬁc societies (ACC, AHA, American Society of An-
esthesiologists, European Society of Anesthesiology, Eu-
ropean Society of Cardiology, International Anesthesia
Research Society, and Society of Cardiovascular Anes-
thesiologists) occurring between January 2011 and April
2013 and searched bibliographies of previous relevant
systematic reviews (18,23–26). No language restrictions
were applied. Unpublished trials were not sought, but
when necessary, we contacted authors of included studies
for additional data.
Methods of Review
Teams of paired reviewers (i.e., D. Duncan and C. Nkonde-
Price, S. S. Virani and J. B. Washam) independently
performed study eligibility screening, study quality
evaluation, and data abstraction. Abstracted data were
entered on previously pilot-tested forms developed
within the DistillerSR (Evidence Partners Inc., Ottawa,
Ontario, Canada) and Indico Clinical Guideline Platform
(Indico Solutions Pty. Ltd., Melbourne, Victoria, Australia)
web-based software platforms. Disagreements were re-
solved through consensus and, where necessary, in-
volvement of a third reviewer (D. N. Wijeysundera). For
each included study, the ERC abstracted details on
participant eligibility criteria, participant number, surgery
types, beta-blocker treatment regimen, participant char-
acteristics (i.e., age, sex, coronary artery disease, prior MI,
current angina), duration of follow-up, and surveillance
protocols for postoperative MI. In addition, the proportion
of participants receiving long-term beta-blocker treat-
ment before recruitment was reported for any included
RCT. We documented the deﬁnition and event rates for
the following outcomes occurring during or within 30
days after surgery: nonfatal MI, all-cause death, cardio-
vascular death, acute stroke, heart failure, signiﬁcant
hypotension, and signiﬁcant bradycardia. Overall study
quality was assessed on the basis of risk of bias, relevance
to the study question, and ﬁdelity of implementation (19).
With regard to evaluation of risk of bias, we used the
Cochrane Collaboration Risk of Bias Tool for RCTs (27) and
the Newcastle-Ottawa Scale for cohort studies (28). A RCT
was assigned an overall rating of low-to-intermediate risk
of bias if the trial was not deemed to be at high risk of bias
for any assessed domain of study quality.
Statistical Analysis
Analyses were performed in STATA Version 13 statistical
software (StataCorp LP, College Station, Texas). Statistical
signiﬁcance was deﬁned by a 2-tailed p value <0.05, and
no adjustment was made for multiple comparisons. Giventhe major methodological differences between RCTs and
cohort studies, the 2 study types were analyzed sepa-
rately. Initially, we assessed both clinical and statistical
heterogeneity across the included studies. Statistical
heterogeneity was characterized with the I2 statistic (29),
which describes the proportion of total variation
explained by between-study variation instead of chance.
Higher I2 statistic values imply more heterogeneity be-
tween studies than would be expected by chance alone.
The random-effects model of DerSimonian and Laird was
used to calculate pooled RRs with 95% CIs (30).
We conducted several prespeciﬁed subgroup analyses
to examine the inﬂuence of the DECREASE and POISE-1
trials on the overall results (5,13,15). First, treatment ef-
fects within the DECREASE trials were compared against
pooled effects in the remaining RCTs. Second, after
excluding the DECREASE trials (i.e., DECREASE-I and
DECREASE-IV) from the analysis, we compared treatment
effects in the POISE-1 trial against pooled effects in the
remaining trials. The rationale for this second subgroup
analysis was to determine whether there was any signal of
a treatment effect independent of the single large RCT
(i.e., the POISE-1 trial) in the meta-analysis. Random-ef-
fects meta-regression was used to test for statistical sig-
niﬁcance of any subgroup effects. The ERC visually
inspected funnel plots to assess for possible publication
bias (31) and also used Egger’s, Harbord’s, and Peters’ tests
to formally test for any funnel plot asymmetry (31–33).
RESULTS
Please see the Online Data Supplement for more
information.
We identiﬁed 17 eligible studies: 16 RCTs and 1 cohort
study (Online Data Supplement 7). The 16 RCTs contrib-
uted data from 12,043 participants (4,5,11–13,15,34–42),
and the cohort study contributed relevant data from
348 participants (43). The characteristics of participants,
surgical procedures, and perioperative beta-blockade
protocols in the included studies are presented in
Tables 1 and 2. Except for the DECREASE-I and DECREASE-
IV trials (5,15), all RCTs began beta-blocker therapywithin 1
day or less prior to surgery.
Of the 16 included RCTs, 8 trials had a low-to-
intermediate overall risk of bias (Online Data Supplement 4)
(4,11–13,38,40,42,44). Fourteen trials showed intermediate-
to-high relevance with regard to their study populations, in-
terventions, and outcomes measures (4,5,11–13,15,35–42), and
10 trials assessed interventions that were implemented with
intermediate-to-high ﬁdelity (Online Data Supplement 4)
(4,5,11–13,37,38,40–42). When assessed with the Newcastle-
Ottawa Scale, the included cohort study did not rate
consistently well across all study quality domains
(Online Data Supplement 5).
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Sixteen RCTs reported effects on nonfatal MI among 11963
participants (Figure 1). Perioperative beta blockade caused
an overall moderate reduction in nonfatal MI, based on a
RR of 0.68 (95% CI: 0.57 to 0.81; p<0.001) with no
measurable statistical heterogeneity (I2¼0%). Nonethe-
less, differences in treatment effects between the
DECREASE trials and the remaining RCTs bordered
on statistical signiﬁcance (p¼0.08). When the DECREASE
trials were excluded (Figure 2), the pooled RR remained
essentially unchanged at 0.72 (95% CI: 0.59 to 0.86), with
no qualitative differences in effects observed between the
POISE-1 trial and the remaining RCTs.Nonfatal Stroke
Nonfatal strokes were reported by 10 trials that included
11 611 participants (Figure 3). Beta blockade caused a sig-
niﬁcant overall increase in the risk of nonfatal stroke (RR:
1.79; 95% CI: 1.09 to 2.95; p¼0.02), with no measurable
statistical heterogeneity (I2¼0%). When DECREASE trials
were excluded (Figure 4), the effects in the POISE-1 trial
(RR: 1.93; 95% CI: 1.01 to 3.68) were qualitatively similar
to those in the remaining trials (RR: 1.72; 95% CI: 0.67
to 4.40).All-Cause Death
Sixteen trials reported effects on rates of all-cause death
among 11,963 participants (Figure 5). There was a statis-
tically signiﬁcant subgroup difference (p¼0.02) between
the DECREASE trials and the remaining RCTs. Among the
DECREASE trials, beta blockade was associated with a
trend toward a reduced risk of all-cause death (RR: 0.42;
95% CI: 0.15 to 1.22; p¼0.11), whereas in the remaining
trials, beta blockers signiﬁcantly increased the risk of all-
cause death (RR: 1.30; 95% CI: 1.03 to 1.63; p¼0.03), with
no measurable statistical heterogeneity (I2¼0%). When
the DECREASE trials were excluded (Figure 6), effects in
the POISE-1 trial (RR: 1.33; 95% CI: 1.03 to 1.73) were
qualitatively similar to effects in the remaining trials (RR:
1.17; 95% CI: 0.70 to 1.94).Cardiovascular Death
Cardiovascular deaths were reported by 13 trials encom-
passing 11,607 participants. There was statistically sig-
niﬁcant evidence of a subgroup difference (p¼0.004)
between the DECREASE trials and the remaining RCTs
(Online Data Supplement 8). Beta blockers signiﬁcantly
reduced the risk of cardiovascular death in the DECREASE
trials (RR: 0.17; 95% CI: 0.05 to 0.64; p¼0.008), whereas
they showed a trend toward an increased risk of cardio-
vascular death (RR: 1.25; 95% CI: 0.92 to 1.71; p¼0.16) in
the remaining trials.Perioperative Adverse Effects
Eight trials reported effects on heart failure among 11,378
participants (Online Data Supplement 9). Overall, beta
blockade had no statistically signiﬁcant effect on periop-
erative heart failure (RR: 1.15; 95% CI: 0.91 to 1.45; p¼0.23),
without measurable statistical heterogeneity (I2¼0%). Ten
trials reported effects on perioperative hypotension or
bradycardia, albeit with highly variable deﬁnitions across
studies (Online Data Supplement 6) (4,11–13,35–38,41,44).
Notably, the DECREASE-I and DECREASE-IV trials did not
separately report rates of hypotension or bradycardia
(5,15). Nine trials reported effects on hypotension among
10,448 participants (Online Data Supplement 10).
Overall, beta blockers signiﬁcantly increased the risk
of perioperative hypotension, with no qualitative differ-
ences in effects seen between the POISE-1 trial (RR: 1.55;
95% CI: 1.38 to 1.74) and other studies (pooled RR: 1.37;
95% CI: 1.20 to 1.56). Signiﬁcant bradycardia was
reported by 9 trials encompassing 10,458 participants
(Online Data Supplement 11). Risks of bradycardia were
signiﬁcantly increased among patients receiving beta
blockers, with no qualitative differences in effects
seen between the POISE-1 trial (RR: 2.74; 95% CI: 2.19
to 3.43) and other studies (pooled RR: 2.41; 95% CI: 1.75
to 3.32).
Post Hoc Analysis
In a post hoc analysis, the ERC excluded the DECREASE
trials and used pooled RRs from the remaining trials to
calculate numbers of avoided or excess nonfatal MIs, all-
cause deaths, and nonfatal strokes per 1,000 population.
Within a hypothetical population with a baseline 6% risk
of nonfatal MI, 2% baseline risk of 30-day all-cause death,
and 0.5% baseline risk of nonfatal stroke, perioperative
beta blockade leads to 17 fewer nonfatal MIs, 6 excess
all-cause deaths, and 4 excess nonfatal strokes in every
1000 treated patients.
Publication Bias
Visual inspection of funnel plots showed no clear evi-
dence of publication bias with regard to effects on
nonfatal MI, nonfatal stroke, heart failure, hypotension,
and bradycardia. These plots did suggest some publica-
tion bias with regard to all-cause and cardiovascular
death. Speciﬁcally, some trials showing an increased
mortality rate with beta blockade may not have been
published. Nonetheless, formal testing did not reveal any
statistically signiﬁcant evidence of publication bias for
any assessed outcomes.
DISCUSSION
This systematic review found the literature to be consis-
tent with regard to effects of perioperative beta blockade
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noncardiac surgery. Previous trials consistently demon-
strated that rates of nonfatal MI were reduced with beta
blockade. Although there may be some differences be-
tween the DECREASE trials and other trials, these differ-
ences relate only to the magnitude of beneﬁt. Whereas the
DECREASE trials found larger and, arguably, somewhat
implausible effect sizes, with RR reductions ranging from
60% to 95% (5,15), other trials had a more realistic, mod-
erate pooled effect size. Available data also consistently
show increased risks of stroke, hypotension, and brady-
cardia with perioperative beta blockade. These ﬁndings
are noteworthy because the increased risk of these com-
plications in the POISE-1 trial has often been attributed
to the trial’s use of high-dose, long-acting metoprolol
(45). The ERC instead found that preceding trials,
despite using different dosing regimens, demonstrated a
consistent signal of increased stroke (albeit statistically
nonsigniﬁcant), as well as signiﬁcant increases in risks
for hypotension and bradycardia. Thus, the increased
risks of these complications appear to be a more general
concern with perioperative beta blockade, as opposed to
one associated only with a speciﬁc drug-dosing regimen.
Notably, there are very few data on stroke, hypotension,
and bradycardia from the DECREASE trials, with the
only reported events being 7 strokes in the DECREASE-
IV trial (15).
The major discrepancy between the DECREASE trials
and the other RCTs relates to effects on all-cause and
cardiovascular death. The DECREASE trials demonstrated
very large reductions in mortality rate, with RR re-
ductions ranging from 58% to 91%. Again, such large
beneﬁts attributable to a single intervention are, argu-
ably, somewhat implausible. Conversely, the remaining
RCTs found a signiﬁcant overall increase in mortality rate.
Although this pooled estimate was dominated by the
POISE-1 trial, which accounted for 80% of the relevant
underlying data, it is noteworthy that even when data
from the POISE-1 trial were excluded, the pooled effect in
the remaining studies was qualitatively similar. Thus,
data at the time of publication suggest that the increased
mortality rate observed in the POISE-1 trial may not be
unique to that speciﬁc dosing protocol.
Inﬂuence of the DECREASE Trials
The DECREASE trials do inﬂuence the overall conclu-
sions of our review, but largely with regard to effects on
mortality rates. Speciﬁcally, in the absence of the
DECREASE trials, other RCTs indicate that beta blockade
signiﬁcantly reduces the risk of postoperative MI but at
the cost of increased rates of stroke, hypotension,
bradycardia, and death. The major change induced by
inclusion of the DECREASE trials in the meta-analysis isa shift of the pooled effect on death to a null effect.
Nonetheless, exclusion of these trials has major impli-
cations for the generalizability of current RCTs to clin-
ical practice. Aside from the DECREASE trials, all RCTs
initiated beta blockade no more than 1 day prior to
surgery. Notably, several cohort studies have shown
that shorter durations (#7 days) of preoperative beta-
blocker therapy are associated with worse outcomes
than are longer durations of preoperative therapy
(46–48). Although some authors have emphasized the
importance of both longer durations of therapy prior to
surgery and preoperative dose-titration to an optimal
heart rate, the evidence for substantial preoperative
modiﬁcation of beta-blocker dosing in the DECREASE
trials is not compelling. Stated otherwise, the vast ma-
jority of patients in these studies presented to surgery
receiving the same dose of bisoprolol on which they
were started. In addition, once the DECREASE trials
were excluded, only 4 included RCTs evaluated oral
beta blockers aside from metoprolol (4,40,41,44).
Importantly, several cohort studies have found meto-
prolol to be associated with worse outcomes than those
seen with more beta-1 selective agents, such as atenolol
or bisoprolol (49–53).
Thus, the strength of evidence that a longer dura-
tion of preoperative therapy with selective oral beta
blockers safely reduces the risk of perioperative MI is
entirely dependent on the DECREASE trials. Such reli-
ance on controversial studies points to the need for
new, adequately powered RCTs of clinically sensible,
perioperative beta-blockade regimens. The ERC pro-
poses that such trials evaluate beta-blockade regimens
started at least several days prior to surgery, preferably
with more beta-1 selective agents. In light of the con-
sistent signals of increased harm associated with beta
blockade initiated very close to surgery, the onus lies
with the perioperative medical community to demon-
strate that such alternative dosing regimens are safe
and efﬁcacious with regard to prevention of perioper-
ative MI.
Limitations
The present systematic review also has several important
limitations. First, exclusion of the DECREASE-I,
DECREASE-IV, and POISE-1 trials leaves few data from
which to make ﬁrm conclusions about the efﬁcacy and
safety of perioperative beta blockade. For example, none
of the pooled effects on MI, death, and stroke were sta-
tistically signiﬁcant within this smaller subgroup of
studies. Consequently, comparison of this subgroup with
the POISE-1 trial focused simply on qualitative compari-
sons of pooled effects. Second, as with most systematic
reviews, our review is limited by the possibility of
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tions used in the original studies. Third, the included
trials did not systematically report treatment effects in
clinically sensible subgroups, such as strata deﬁned by
Revised Cardiac Risk Index scores (54). Several prior
observational studies have suggested that the treatment
effects of perioperative beta blockade vary across these
strata, with beneﬁts conﬁned to high-risk individuals who
have at least 2 to 3 clinical risk factors (50,55). Further
exploration of such subgroup differences within the
context of RCTs will entail an individual patient data
meta-analysis. Fourth, we did not adjust for multiple
comparisons when conducting subgroup analyses. The
results of these subgroup analyses should therefore be
viewed as hypothesis generating as opposed to deﬁnitive.
Fifth, in spite of an extensive literature search for
observational studies, only 1 cohort study was included
in this systematic review (43). Despite still informing an
overall understanding of the risks and beneﬁts of beta
blockade in noncardiac surgery, several potentially
relevant observational studies did not meet our inclu-
sion criteria (50,55,56). For example, a 2005 multicenter
cohort study did not capture preadmission beta-blocker
use (55). Thus, the investigators could not differentiate
between ongoing, long-term beta-blocker use and new
perioperative beta-blocker use for cardiac risk reduc-
tion. Similarly, a 2010 single-center study also included
patients undergoing cardiac surgery and grouped all
individuals receiving beta blockers prior to surgery into
a single category, regardless of the duration of preop-
erative therapy (56). Most recently, a 2013 multicenter
cohort study deﬁned perioperative beta blockade on the
basis of on any relevant prescription on either the day
of surgery or the subsequent day (50). Nonetheless, the
study did not analyze the dose or duration of inpatient
beta-blocker prescriptions; hence, it did not meet our
criterion for minimum duration of postoperative beta-
blocker therapy. Additionally, the data sources in all 3
studies could not differentiate between beta blockade
for preventing cardiac events and beta blockade for
treating postoperative complications (e.g., myocardial
ischemia). The importance of distinguishing between
prophylactic and therapeutic interventions is under-
scored by the observation that, in some RCTs of peri-
operative beta blockade, 7% to 10% of participants
in the control arm still received open-label beta
blockers, possibly to treat new postoperative compli-
cations (4,12).Conclusions
In summary, this systematic review found that perioper-
ative beta blockade started within 1 day or less before
noncardiac surgery helps prevent nonfatal MI but at the
cost of increased risks of stroke, death, hypotension, and
bradycardia. The DECREASE-I and DECREASE-IV trials
differed from other trials with regard to design in that
they are the only RCTs that assessed beta blockade started
2 or more days before surgery. Their results differed
signiﬁcantly from other RCTs in that perioperative mor-
tality rate was decreased, as opposed to increased, with
beta-blocker therapy. In the absence of these controver-
sial studies, there are insufﬁcient robust data on the ef-
ﬁcacy and safety of perioperative beta-blocker regimens
that use agents aside from metoprolol or initiate treat-
ment 2 to 45 days prior to surgery.
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TABLE 1 Summary of Included Studies
Study (Year) N
Inclusion
Criteria
Exclusion
Criteria
Types of
Surgery
Long-Term
Preoperative
Beta-Blocker
Therapy
Participant
Characteristics
Randomized Controlled
Trials
Mangano et al. (1996) (4)
8929262
200 Known CAD or $2 risk
factors ($65 y of age,
hypertension, current
smoker, elevated
cholesterol level,
diabetes mellitus)
Pacemaker dependency,
resting ECG
abnormalities (left
bundle-branch block,
marked ST-T
abnormalities)
Elective vascular (41%),
intra-abdominal (21%),
orthopedic (14%),
neurosurgical (9%), or
other (16%)
procedures
13% Mean age 67.5 y, 39%
with known CAD
Jakobsen et al. (1997) (34)
9327317
100 Pts undergoing
thoracotomy for lung
resection with no known
current or previous
cardiovascular disease
NR Intrathoracic (100%)
procedures
NR 66% males, mean
age 60.4 y
Bayliff et al. (1999) (35)
10086546
99 Pts >18 y of age
undergoing major
thoracic operation
Prior beta-blocker use,
asthma, HF, heart
block, supraventricular
tachyarrhythmias, prior
speciﬁc drug use (digoxin,
quinidine, procainamide,
amiodarone, diltiazem,
verapamil)
Intrathoracic
(100%)
procedures
0% 62% males, mean age
62.5 y, 6% with
prior MI, 5% with
current angina
DECREASE-I (1999) (5)
10588963
112 Pts with $1 cardiac risk
factor (>70 y of age,
angina; prior MI, HF,
diabetes mellitus, limited
exercise capacity,
ventricular arrhythmias)
and positive result on
dobutamine stress
echocardiography.
Prior beta-blocker use,
asthma, very high-risk
dobutamine stress
echocardiography result
(extensive wall-motion
abnormalities, strong
evidence of left main or
severe 3-vessel CAD)
Major vascular
(100%) procedures
0% 87% males, mean age
67.5 y, 100% with
known CAD, 52% with
prior MI, 32% with
current angina
Raby et al. (1999) (36)
10071990
26 Pts with preoperative
myocardial ischemia
detected by 24-h ECG
monitoring performed
within 1–12 d before
surgery
Baseline ST-T
abnormalities on ECG
that preclude accurate
interpretation of ECG
monitoring for ischemia
Major vascular
(100%) procedures
35% 46% males, mean age
68.1 y, 38% with prior
MI or current angina
Zaugg et al. (1999)* (44)
10598610
43 Pts $65 y of age Prior beta-blocker use,
other prior drugs (beta-
adrenergic agonists,
glucocorticoids,
anticonvulsants), heart
block, rhythm other than
sinus on ECG, HF,
bronchospasm, systemic
infection, neurological
disorders
Intra-abdominal (81%),
orthopedic (7%),
and other (12%)
procedures
0% 40% males, mean age
74.6 y, 37% with
known CAD
Urban et al. (2000) (37)
10825304
107 Pts 50–80 y of age
undergoing elective
total knee arthroplasty
with known CAD or $1 risk
factor ($65 y of age,
hypertension, current
smoker, elevated
cholesterol level,
diabetes mellitus)
Speciﬁc ECG
abnormalities (heart
block, bundle-branch
block, atrial arrhythmias,
LV hypertrophy with
repolarization
abnormalities),
LVEF <30%, symptomatic
mitral or aortic valvular
disease, bronchospasm
Orthopedic (100%)
procedures
28% Mean age 69.5 y, 17%
with prior MI, 31%
with current angina
POBBLE (2005) (38)
15874923
103 Pts undergoing major
elective infrarenal
vascular surgery under
general anesthesia
Prior MI in past 2 y,
unstable angina, positive
dobutamine stress test,
prior beta-blocker use,
asthma, aortic stenosis,
heart rate #45 beats/min,
systolic BP <100 mm Hg
Major vascular
procedures (100%)
0% 78% males, median
age 73 y
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TABLE 1 Continued
Study (Year) N
Inclusion
Criteria
Exclusion
Criteria
Types of
Surgery
Long-Term
Preoperative
Beta-Blocker
Therapy
Participant
Characteristics
DIPOM (2006) (11)
16793810
921 Pts with diabetes
mellitus >39 y of age
undergoing noncardiac
surgery with expected
duration >1 h
Long-term beta-blocker
use, conditions indicating
beta blocker treatment,
severe HF, heart block
Orthopedic (33%),
intra-abdominal (28%),
neurosurgical (8%),
vascular (7%),
gynecological (5%), and
other (19%) procedures
0% 59% males, mean age
64.9 y, 8% with prior
MI, 11% with current
angina
Lai et al. (2006) (39)
16687084
60 Pts $65 y of age
undergoing
esophagectomy for
esophageal cancer
with no known
prior CAD
Prior beta-blocker use,
heart rate #55 beats/min,
systolic BP #100 mm Hg,
heart block
Intrathoracic (100%)
procedures
0% 82% males, median ages
66 y (beta blocker arm)
and 67 y (control arm),
MaVS (2006) (12)
17070177
496 Pts (ASA-PS Class #3)
undergoing major
vascular (abdominal
aortic repair, infra-inguinal,
or axillo-femoral
bypass) surgery
Long-term beta-blocker
use, current amiodarone
use, reactive airways
disease, HF, heart block
Major vascular (100%)
procedures
0% 76% males, mean age 66.1
y, 14% with prior MI, 9%
with current angina
Neary et al. (2006) (40)
16764198
38 Pts undergoing
emergency surgery
with $1 of the following
criteria: CAD,
cerebrovascular disease
(prior stroke or TIA), $2
minor risk criteria ($65 y of
age, hypertension, smoker,
diabetes mellitus,
hypercholesterolemia)
Prior beta-blocker use,
heart rate <55 beats/min,
heart block, chronic
obstructive airway disease,
asthma, cardiovascular
collapse, uncorrected
hypovolemia
Intra-abdominal (29%),
amputation (24%), major
vascular (21%), orthopedic
(16%), and other (10%)
procedures
0% NR
BBSA (2007) (41)
17585213
219 Pts undergoing surgery
with spinal anesthesia with
known CAD or $2 risk
factors ($65 y of age,
hypertension, current
smoker, elevated
cholesterol level, diabetes
mellitus)
Prior beta-blocker use,
signiﬁcant HF, heart
block, severe asthma,
left bundle-branch
block
Orthopedic (67%),
urologic (25%),
and other (8%)
procedures
0% 55% males, mean age 70.0
y, 8% with prior MI, 6%
with current angina
POISE-1 (2008) (13)
18479744
8,351 Pts $45 y of age and
$1 of the following criteria:
CAD, PAD, stroke,
hospitalization for HF within
past 3 y, major vascular
surgery, or $3 minor risk
factors (HF, TIA, diabetes
mellitus, renal insufﬁciency,
age >70 y, nonelective
surgery, intrathoracic
surgery, or intraperitoneal
surgery)
Prior beta-blocker use,
verapamil use, heart
rate <50 beats/min, heart
block, asthma, CABG
surgery in previous 5 y with
no subsequent ischemia,
low-risk surgery
Vascular (41%),
intraperitoneal (22%),
orthopedic (21%),
and other (16%)
procedures
0% 63% males, mean age
69.0 y, 43% with known
CAD
Yang et al. (2008) (42)
18953854
102 Pts $45 y of age with
$1 of the following criteria:
CAD, PAD, stroke,
hospitalization for HF in
prior 3 y, or $3 minor risk
factors (HF, diabetes
mellitus, $65 y of age,
hypertension,
hypercholesterolemia,
smoker, intrathoracic
surgery, or intraperitoneal
surgery)
Prior beta-blocker use,
heart rate <50 beats/min,
cardiac pacemaker, heart
block, asthma, chronic
obstructive pulmonary
disease
Intra-abdominal and
intrathoracic procedures
0% 59% males, mean
age 71.0 y
DECREASE-IV (2009) (15)
19474688
1,066 Pts $40 y of age
undergoing elective
noncardiovascular
surgery with an
estimated 1%–6%
perioperative
cardiovascular risk
Current use, or
contraindication to
use, of beta
blockers or statins
General surgical (39%),
urologic (19%), orthopedic
(16%), ear-nose-throat
(12%), and other surgical
(14%) procedures
0% 60% males, mean age
65.4 y, 6% with current
angina, 5% with previous
MI
Continued on the next page
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TABLE 1 Continued
Study (Year) N
Inclusion
Criteria
Exclusion
Criteria
Types of
Surgery
Long-Term
Preoperative
Beta-Blocker
Therapy
Participant
Characteristics
Cohort Studies
Matyal et al. (2008)†(43)
18503921
348 Pts undergoing supra-
and infrainguinal
vascular surgery
NR Major vascular (100%)
procedures
0%† 60% males
*Information on 2 of the study arms (preoperative/postoperative atenolol versus no beta-blocker therapy). The third study arm (intraoperative atenolol) did not meet the review
deﬁnition for eligible perioperative beta-blockade.
†Only data on the subgroup of 348 pts who were not previously receiving preoperative long-term beta-blocker therapy.
ASA-PS indicates American Society of Anesthesiologists Physical Status; BBSA, Beta Blocker in Spinal Anesthesia; BP, blood pressure; CABG, coronary artery bypass graft; CAD,
coronary artery disease; DECREASE, Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography; DIPOM, Diabetic Postoperative Mortality and Morbidity; ECG,
electrocardiogram; HF, heart failure; LV, left ventricular; LVEF, left ventricular ejection fraction; MaVS, Metoprolol After Vascular Surgery; MI, myocardial infarction; NR, not reported;
PAD, peripheral arterial disease; POBBLE, Perioperative Beta Blockade; POISE, Perioperative Ischemic Evaluation; pts, patients; and TIA, transient ischemic attack.
TABLE 2 Perioperative Beta-Blocker Regimens, Duration of Follow-Up, and Comparison Arms in Included Studies
Study (Year)
Beta-Blocker
Type
Perioperative
Beta-Blocker
Regimen
Preoperative
Beta-Blocker
Dose-Titration
Duration of
Postoperative
Treatment
Control
Arm
Routine
Surveillance
for
Postoperative
MI
Duration of
Postoperative
Follow-Up
Randomized Controlled
Trials
Mangano et al. (1996) (4)
8929262
Atenolol IV atenolol 5–10 mg
immediately prior to
surgery, and oral atenolol
50–100 mg once daily for
up to 7 d after surgery
None 7 d or hospital
discharge
Placebo Yes 2 y
Jakobsen et al. (1997) (34)
9327317
Metoprolol
tartrate
Oral metoprolol 100 mg
90 min prior to surgery,
and continued once daily
for 4–10 d after surgery
None 4–10 d Placebo No 4–10 d
Bayliff et al. (1999) (35)
10086546
Propranolol Oral propranolol 10 mg
started prior to surgery
(timing not deﬁned) and
continued every 6 h for
5 d after surgery
None 5 d Placebo No Hospital
discharge
DECREASE-I (1999) (5)
10588963
Bisoprolol Oral bisoprolol 5–10 mg
once daily starting at least
7 d prior to surgery, and
continued for 30 d after
surgery
Yes–titration occurred
over $7 (average
37) d prior to surgery.
In 75% of pts, the
starting dose was not
changed.
30 d No beta-
blocker
therapy
Yes 30 d
Raby et al. (1999) (36)
10071990
Esmolol IV esmolol 100–300 mcg/kg/
min starting after surgery
and continued for 48 h
None 2 d Placebo No 2 d
Zaugg et al. (1999)* (44)
10598610
Atenolol IV atenolol 5–10 mg 30 min
prior to surgery, and
continued twice daily for
3 d after surgery
None 3 d No beta-
blocker
therapy
Yes 3 d
Urban et al. (2000) (37)
10825304
Esmolol
(intraoperative),
metoprolol
tartrate
(postoperative)
IV esmolol 250 mg/h started
1 h after surgery, which was
then substituted by oral
metoprolol 25–50 mg on
the ﬁrst morning after
surgery. Beta-blocker
therapy was continued for
2 d after surgery.
None 2 d No beta-
blocker
therapy
No 2 d
POBBLE (2005) (38)
15874923
Metoprolol
tartrate
Oral metoprolol 25–50 mg
twice daily starting 1 d prior
to surgery (minimum of
2 preoperative doses) and
continued for 7 d after
surgery. In addition, IV
metoprolol (2–4 mg) was
given during surgery.
None 7 d Placebo Yes 30 d
Continued on the next page
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TABLE 2 Continued
Study (Year)
Beta-Blocker
Type
Perioperative
Beta-Blocker
Regimen
Preoperative
Beta-Blocker
Dose-Titration
Duration of
Postoperative
Treatment
Control
Arm
Routine
Surveillance
for
Postoperative
MI
Duration of
Postoperative
Follow-Up
DIPOM (2006) (11)
16793810
Metoprolol
succinate
Oral metoprolol 50–100 mg
1 d prior to surgery, and
continued once daily for up
to 8 d after surgery
None Hospital
discharge
Placebo Yes Median 18 mo
follow-up
(range
6–30 mo)
Lai et al. (2006) (39)
16687084
Metoprolol
tartrate
IV metoprolol 0.06-mg/kg
boluses started immediately
prior to surgery and
repeated as needed to
achieve target heart rates
during surgery. After
surgery, this IV regimen
was substituted by oral
metoprolol 25 mg 3 times
daily and continued for
3 d after surgery.
None 3 d No beta
blocker
therapy
Yes 3 d
MaVS (2006) (12)
17070177
Metoprolol
tartrate
Oral metoprolol 25–100 mg
2 h prior to surgery, and
continued twice daily for up
to 5 d after surgery
None 5 d or hospital
discharge
Placebo Yes 6 mo
Neary et al. (2006) (40)
16764198
Atenolol IV atenolol 1.25 mg
starting with surgery, and
repeated every 30 min up
to a maximum of 5 mg.
After surgery, oral atenolol
50 mg once daily was
continued for 7 d after
surgery.
None 7 d Placebo Yes 1 y
BBSA (2007) (41)
17585213
Bisoprolol Oral bisoprolol 5–10 mg 3 h
prior to surgery, and
continued once daily for up to
10 d after surgery
None 10 d or hospital
discharge
Placebo Yes 1 y
POISE-1 (2008) (13)
18479744
Metoprolol
succinate
Oral metoprolol 100 mg
within 2–4 h prior to surgery,
and oral metoprolol 100–200
mg once daily for 30 d after
surgery
None 30 d Placebo Yes 30 d
Yang et al. (2008) (42)
18953854
Metoprolol
tartrate
Oral metoprolol 25 mg
within 2 h prior to surgery,
followed by titrated IV
(immediately after surgery)
and oral (remaining
postoperative period)
metoprolol for 30 d after
surgery
None 30 d Placebo Yes 30 d
DECREASE-IV (2009) (15)
19474688
Bisoprolol Oral bisoprolol 2.5–10 mg
once daily started at
least 21 d prior to surgery,
and continued for
30 d after surgery
Yes–titration
occurred over $21
(median 34) d prior
to surgery. In 99% of pts,
the starting dose was
not changed.
30 d No beta-
blocker
therapy
Yes 30 d
Cohort Studies
Matyal et al. (2008) (43)
18503921
Not deﬁned Beta-blocker therapy started
immediately prior to or after
surgery, and continued for up
to 3 d after surgery
Not described
(observational study)
3 d or hospital
discharge
No beta-
blocker
therapy
No routine
surveillance
Hospital
discharge
*Information on 2 of the study arms (preoperative/postoperative atenolol versus no beta-blocker therapy). The third study arm (intraoperative atenolol) did not meet the review
deﬁnition for eligible perioperative beta blockade.
BBSA indicates Beta Blocker in Spinal Anesthesia; DECREASE, Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography; DIPOM, Diabetic Postoperative
Mortality and Morbidity; IV, intravenous; MaVS, Metoprolol After Vascular Surgery; MI, myocardial infarction; POBBLE, Perioperative Beta Blockade; POISE, Perioperative Ischemic
Evaluation; and pts, patients.
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FIGURE 1 Effect of Perioperative Beta Blockade on In-Hospital or 30-Day Nonfatal MI in RCTs Within Subgroups Deﬁned by DECREASE Trials Versus
Other Trials
The pooled effect is expressed as a pooled RR with associated 95% CI. The solid black diamonds represent point estimates in individual RCTs. The area of each
gray square correlates with its contribution toward the pooled summary estimates. Horizontal lines denote 95% CIs. Estimates to the left of the line of unity
(i.e., RR: 1) indicate superior clinical outcomes (i.e., fewer nonfatal MIs) with beta blockade (“Favors Beta-Blockers”), whereas estimates to the right of the line
of unity indicate superior clinical outcomes with control (“Favors Control”). The blue diamonds represent the pooled estimates for all studies (RR: 0.68; 95%
CI: 0.57–0.81; p<0.001), as well as the DECREASE subgroup (RR: 0.22; 95% CI: 0.03–1.48; p¼0.12) and the subgroup of other trials (RR: 0.72; 95% CI:
0.59–0.86; p<0.001). Statistical heterogeneity, as measured by the I2 statistic, was 0% for the overall analysis, 52.6% for DECREASE subgroup, and 0% for
the subgroup of other trials. Differences between pooled estimates from the 2 subgroups bordered on statistical signiﬁcance (p¼0.08).
BBSA indicates Beta Blocker in Spinal Anesthesia; CI, conﬁdence interval; DECREASE, Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress
Echocardiography; DIPOM, Diabetic Postoperative Mortality and Morbidity; MaVS, Metoprolol After Vascular Surgery; MI, myocardial infarction; POBBLE,
Perioperative Beta Blockade; POISE, Perioperative Ischemic Evaluation; RCT, randomized controlled trial; and RR, relative risk.
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FIGURE 2 Effect of Perioperative Beta Blockade on In-Hospital or 30-Day Nonfatal MI in RCTs After Exclusion of the DECREASE Family of Trials,
Within Subgroups Deﬁned by the POISE-1 Trial Versus Other Trials
The pooled effect is expressed as a pooled RR with associated 95% CI. The solid black diamonds represent point estimates in individual RCTs. The area of
each gray square correlates with its contribution toward the pooled summary estimates. Horizontal lines denote 95% CIs. Estimates to the left of the line of
unity (i.e., RR: 1) indicate superior clinical outcomes (i.e., fewer nonfatal MIs) with beta blockade (“Favors Beta-Blockers”), whereas estimates to the right of
the line of unity indicate superior clinical outcomes with control (“Favors Control”). The blue diamonds represent the pooled estimates for all studies (RR:
0.72; 95% CI: 0.59–0.86), as well as the POISE-1 trial (RR: 0.70; 95% CI: 0.57–0.86) and the subgroup of other trials (RR: 0.76; 95% CI: 0.47–1.21).
Statistical heterogeneity, as measured by the I2 statistic, was 0% for the overall analysis.
BBSA indicates Beta Blocker in Spinal Anesthesia; CI, conﬁdence interval; DECREASE, Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress
Echocardiography; DIPOM, Diabetic Postoperative Mortality and Morbidity; MaVS, Metoprolol After Vascular Surgery; MI, myocardial infarction; POBBLE,
Perioperative Beta Blockade; POISE, Perioperative Ischemic Evaluation; RCT, randomized controlled trial; and RR, relative risk.
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FIGURE 3 Effect of Perioperative Beta Blockade on In-Hospital or 30-Day Nonfatal Stroke in RCTs Within Subgroups Deﬁned by DECREASE Trials
Versus Other Trials
The pooled effect is expressed as a pooled RR with associated 95% CI. The solid black diamonds represent point estimates in individual RCTs. The area of
each gray square correlates with its contribution toward the pooled summary estimates. Horizontal lines denote 95% CIs. Estimates to the left of the line of
unity (i.e., RR: 1) indicate superior clinical outcomes (i.e., fewer nonfatal strokes) with beta blockade (“Favors Beta-Blockers”), whereas estimates to the right
of the line of unity indicate superior clinical outcomes with control (“Favors Control”). The blue diamonds represent the pooled estimates for all studies
(RR: 1.79; 95% CI: 1.09–2.95; p¼0.02), as well as the DECREASE subgroup (RR: 1.33; 95% CI: 0.30–5.93; p¼0.71) and the subgroup of other trials (RR: 1.86;
95% CI: 1.09–3.16; p¼0.02). Statistical heterogeneity, as measured by the I2 statistic, was 0% for the overall analysis.
BBSA indicates Beta Blocker in Spinal Anesthesia; CI, conﬁdence interval; DECREASE, Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress
Echocardiography; DIPOM, Diabetic Postoperative Mortality and Morbidity; MaVS, Metoprolol After Vascular Surgery; POBBLE, Perioperative Beta Blockade;
POISE, Perioperative Ischemic Evaluation; RCT, randomized controlled trial; and RR, relative risk.
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FIGURE 4 Effect of Perioperative Beta Blockade on In-Hospital or 30-Day Nonfatal Stroke in RCTs After Exclusion of the DECREASE Family of Trials,
Within Subgroups Deﬁned by the POISE-1 Trial Versus Other Trials
The pooled effect is expressed as a pooled RR with associated 95% CI. The solid black diamonds represent point estimates in individual RCTs. The area of
each gray square correlates with its contribution toward the pooled summary estimates. Horizontal lines denote 95% CIs. Estimates to the left of the line of
unity (i.e., RR: 1) indicate superior clinical outcomes (i.e., fewer nonfatal strokes) with beta blockade (“Favors Beta-Blockers”), whereas estimates to the right
of the line of unity indicate superior clinical outcomes with control (“Favors Control”). The blue diamonds represent the pooled estimates for all studies
(RR: 1.86; 95% CI: 1.09–3.16), as well as the POISE-1 trial (RR: 1.93; 95% CI: 1.01–3.68) and the subgroup of other trials (RR: 1.72; 95% CI: 0.67–4.40).
Statistical heterogeneity, as measured by the I2 statistic, was 0% for the overall analysis.
BBSA indicates Beta Blocker in Spinal Anesthesia; CI, conﬁdence interval; DECREASE, Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress
Echocardiography; DIPOM, Diabetic Postoperative Mortality and Morbidity; MaVS, Metoprolol After Vascular Surgery; POBBLE, Perioperative Beta Blockade;
POISE, Perioperative Ischemic Evaluation; RCT, randomized controlled trial; and RR, relative risk.
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FIGURE 5 Effect of Perioperative Beta Blockade on In-Hospital or 30-Day Mortality Rate in RCTs Within Subgroups Deﬁned by DECREASE Trials
Versus Other Trials
The pooled effect is expressed as a pooled RR with associated 95% CI. The solid black diamonds represent point estimates in individual RCTs. The area of
each gray square correlates with its contribution toward the pooled summary estimates. Horizontal lines denote 95% CIs. Estimates to the left of the line of
unity (i.e., RR: 1) indicate superior clinical outcomes (i.e., fewer deaths) with beta blockade (“Favors Beta-Blockers”), whereas estimates to the right of the
line of unity indicate superior clinical outcomes with control (“Favors Control”). The blue diamonds represent the pooled estimates for all studies (RR: 0.96;
95% CI: 0.62–1.47; p¼0.84), as well as the DECREASE subgroup (RR: 0.42; 95% CI: 0.15–1.22; p¼0.11) and the subgroup of other trials (RR: 1.30; 95% CI:
1.03–1.63; p¼0.03). Statistical heterogeneity, as measured by the I2 statistic, was 35.1% for the overall analysis, 43.6% for DECREASE subgroup, and 0% for
the subgroup of other trials. There was statistically signiﬁcant evidence (p¼0.02) of a difference between the pooled estimates in the 2 subgroups.
BBSA indicates Beta Blocker in Spinal Anesthesia; CI, conﬁdence interval; DECREASE, Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress
Echocardiography; DIPOM, Diabetic Postoperative Mortality and Morbidity; MaVS, Metoprolol After Vascular Surgery; POBBLE, Perioperative Beta Blockade;
POISE, Perioperative Ischemic Evaluation; RCT, randomized controlled trial; and RR, relative risk.
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FIGURE 6 Effect of Perioperative Beta Blockade on In-Hospital or 30-Day Mortality Rate in RCTs After Exclusion of the DECREASE Family of Trials,
Within Subgroups Deﬁned by POISE-1 Trial Versus Other Trials
The pooled effect is expressed as a pooled RR with associated 95% CI. The solid black diamonds represent point estimates in individual RCTs. The area of
each gray square correlates with its contribution toward the pooled summary estimates. Horizontal lines denote 95% CIs. Estimates to the left of the line of
unity (i.e., RR: 1) indicate superior clinical outcomes (i.e., fewer deaths) with beta blockade (“Favors Beta-Blockers”), whereas estimates to the right of the
line of unity indicate superior clinical outcomes with control (“Favors Control”). The blue diamonds represent the pooled estimates for all studies (RR: 1.30;
95% CI: 1.03–1.63), as well as the POISE-1 trial (RR: 1.33; 95% CI: 1.03–1.73) and the subgroup of other trials (RR: 1.17; 95% CI: 0.70–1.94). Statistical
heterogeneity, as measured by the I2 statistic, was 0% for the overall analysis.
BBSA indicates Beta Blocker in Spinal Anesthesia; CI, conﬁdence interval; DECREASE, Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress
Echocardiography; DIPOM, Diabetic Postoperative Mortality and Morbidity; MaVS, Metoprolol After Vascular Surgery; POBBLE, Perioperative Beta Blockade;
POISE, Perioperative Ischemic Evaluation; RCT, randomized controlled trial; and RR, relative risk.
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